ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program

Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with application submissions open through June 11, 2025

LAVAL, QC / ACCESS Newswire / April 10, 2025 / Bausch Health Companies Inc. (NYSE: BHC)(TSX:BHC)and its dermatology business, Ortho Dermatologics, today announced the 2025 ASPIRE HIGHER Scholarship Program is now open for application submissions through June 11, 2025. The program will award six exceptional students, impacted by dermatologic conditions, a scholarship of up to $10,000 in support of their higher education goals.

"It is our distinct honor to continue the ASPIRE HIGHER Scholarship Program to help support students affected by dermatologic conditions, and to recognize and thank the dedicated healthcare providers who treat them. We are truly inspired by our students' perseverance as they work to achieve their educational dreams," said Donald Pearl, Senior Vice President, Ortho Dermatologics, Bausch Health.

Students can apply for this scholarship by completing the online application, writing an essay on the impact of having a diagnosed dermatologic condition and the role that a health care provider played in helping to manage their condition, and two reference letters. Scholarships are offered to school applicants or current attendees of a two- or four-year college, university, or an advanced (post-high school) vocational or technical school for the 2025 - 2026 academic year and are available in the following categories:

  • 3 Undergraduate Scholar Awards - for students pursuing undergraduate or vocational/technical degrees.

  • 3 Graduate Scholar Awards - for students pursuing graduate degrees.

The application period for the ASPIRE HIGHER Scholarship Program will close on June 11, 2025, and scholarship recipients will be notified in July of 2025. To learn more about the scholarship, including eligibility criteria, terms and conditions, and stories from previous winners, please visit www.aspirehigherscholarships.com.

About Bausch Health

Bausch Health Companies Inc. (NYSE: BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our dermatology business, Ortho Dermatologics is one of the largest prescription and aesthetic dermatology businesses dedicated to helping patients in the treatment of a range of conditions, including psoriasis, onychomycosis, actinic keratosis, acne, atopic dermatitis and other dermatoses. More information can be found at https://www.ortho-dermatologics.com and connect with us on LinkedIn. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.

©2025 Ortho Dermatologics' or its affiliates.

Investor Contact:
Garen Sarafian
ir@bauschhealth.com
877-281-6642 (toll-free)

Media Contact:
Katie Savastano
corporate.communications@bauschhealth.com
(908) 569-3692

SOURCE: Bausch Health Companies Inc



View the original press release on ACCESS Newswire

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.53
+0.42 (0.18%)
AAPL  278.78
-1.92 (-0.68%)
AMD  217.97
+1.99 (0.92%)
BAC  53.95
+0.07 (0.13%)
GOOG  322.09
+3.70 (1.16%)
META  673.42
+11.89 (1.80%)
MSFT  483.16
+2.32 (0.48%)
NVDA  182.41
-0.97 (-0.53%)
ORCL  217.58
+3.25 (1.52%)
TSLA  455.00
+0.47 (0.10%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.